Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921490 | 0.96 | TRPA1 (0.53) | TRPA1HDAC3MAPK1ADRA1AHDAC4 | |
| Hydrochloric Acid SCHEMBL8852295 | 0.94 | TRPA1 (0.51) | TRPA1HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL7285852 | 0.92 | TDP1 (0.52) | TRPA1HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL20019603 | 0.92 | TDP1 (0.52) | TRPA1HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL19682101 | 0.91 | TRPA1 (0.67) | TRPA1TRPV1SIGMAR1MAOAMAPT | |
| SCHEMBL19511634 | 0.90 | TRPA1 (0.49) | TRPA1ADRA1ASLC6A3SIGMAR1HTR2A | |
| SCHEMBL7549946 | 0.90 | TRPA1 (0.49) | TRPA1HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL7549945 | 0.90 | TRPA1 (0.49) | TRPA1HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL3652085 | 0.90 | SIGMAR1 (0.49) | TRPA1HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL14402447 | 0.90 | SIGMAR1 (0.49) | TRPA1HDAC3MAPK1ADRA1AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980620-B2 | Petroleum bioconversion of organic acids to prevent refinery corrosion | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATURAL RESOURCES (CA) | 2015-03-17 | — | — | US | disclosed |
| US-20120034683-A1 | PETROLEUM BIOCONVERSION OF ORGANIC ACIDS TO PREVENT REFINERY CORROSION | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATURAL RESOURCES (CA) | 2012-02-09 | — | — | US | disclosed |
| US-7056935-B2 | Rotamase enzyme activity inhibitors | GPI NIL HOLDINGS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-6544987-B2 | Pyrrolidine or piperidine sulfonyl compounds; stimulate neurite outgrowth in nerve cells leading to nerve regeneration for treatment of hair loss, memory loss or vision disorders | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |
| EP-0662958-B1 | 1-(2-OXO-ACETYL)-PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES AS MULTI-DRUG-RESISTENT CANCER CELL SENSITIZERS | VERTEX PHARMA (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1237869-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR STIMULATING NEURONAL GROWTH AND ELONGATION | AGOURON PHARMACEUTICALS, INC. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020061881-A1 | Compounds, compositions, and methods for stimulating neuronal growth and elongation | AGOURON PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | GLIAMED, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | GUILFORD PHARMACEUTICALS INC. | 2002-04-11 | — | — | US | disclosed |
| EP-1117372-A2 | METHOD OF TREATING HAIR LOSS USING SULFONAMIDES | THE PROCTER & GAMBLE COMPANY (US) | 2001-07-25 | — | — | EP | disclosed |
| US-5620971-A | Biologically active acylated amino acid derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-04-15 | — | — | US | disclosed |
| US-5545750-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0662958-A1 | 1-(2-OXO-ACETYL)-PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES AS MULTI-DRUG-RESISTENT CANCER CELL SENSITIZERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994007858-A1 | 1-(2-OXO-ACETYL)-PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES AS MULTI-DRUG-RESISTENT CANCER CELL SENSITIZERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-04-14 | — | — | WO | disclosed |
| EP-0587756-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-23 | — | — | EP | disclosed |
| EP-0584223-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992021313-A2 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1992-12-10 | — | — | WO | disclosed |
| WO-1992019593-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1992-11-12 | — | — | WO | disclosed |
| US-5142056-A | Human immunodeficiency virus protease inhibitor | ABBOTT LABORATORIES (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | FKBP14, FKBP1A, FKBP2 | TRPA1 2823/4885HDAC3 1312/4885MAPK1 3247/4885 |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | BDNF, FKBP1A, FKBP14 | TRPA1 4650/4885HDAC3 2967/4885MAPK1 1752/4885 |
| US-20020061881-A1 | Compounds, compositions, and methods for stimulating neuronal growth and elongation | NGF, GAP43, BDNF | TRPA1 4663/4885HDAC3 2280/4885MAPK1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.